S

Sage Therapeutics
D

SAGE

5.61000
USD
0.61
(12.09%)
Market Closed
Volume
0
EPS
-6
Div Yield
-
P/E
-1
Market Cap
343,182,005
OverviewSignalsIdeasNews
Related Instruments
    C
    CLLS
    0.00000
    (0.00%)
    1.58000 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    F
    FOLD
    0.07500
    (0.77%)
    9.81000 USD
    Q
    QURE
    1.550
    (10.00%)
    17.050 USD
    R
    RCKT
    0.225
    (1.98%)
    11.570 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    More
News

Title: Sage Therapeutics

Sector: Healthcare
Industry: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.